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Background: Placebo-controlled trials play an important role in the evaluation of healthcare interven-
tions. However, they can be challenging to design and deliver for invasive interventions, including surgery.
In-depth understanding of the component parts of the treatment intervention is needed to ascertain what
should, and should not, be delivered as part of the placebo. Assessment of risk to patients and strategies
to ensure that the placebo effectively mimics the treatment are also required. To date, no guidance exists
for the design of invasive placebo interventions. This study aimed to develop a framework to optimize the
design and delivery of invasive placebo interventions in RCTs.
Methods: A preliminary framework was developed using published literature to: expand the scope of
an existing typology, which facilitates the deconstruction of invasive interventions; and identify placebo
optimization strategies. The framework was refined after consultation with key stakeholders in surgical
trials, consensus methodology and medical ethics.
Results: The resulting DITTO framework consists of five stages: deconstruct treatment intervention
into constituent components and co-interventions; identify critical surgical element(s); take out the
critical element(s); think risk, feasibility and role of placebo in the trial when considering remaining
components; and optimize placebo to ensure effective blinding of patients and trial personnel.
Conclusion: DITTO considers invasive placebo composition systematically, accounting for risk, feasibil-
ity and placebo optimization. Use of the framework can support the design of high-quality RCTs, which
are needed to underpin delivery of healthcare interventions.
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Introduction
Randomized controlled trials (RCTs) involving placebo
comparators have an important role in the evaluation of
healthcare interventions. A key advantage is that they
allow estimation of the true effect of the treatment under
evaluation by quantifying the placebo response: the effects
of concomitant non-treatment factors, such as setting,
patient expectations, interactions with health profession-
als and the natural course of the disease/condition1–3.
Placebo-controlled RCTs also provide the methodological
ideal in terms of blinding of patients, trial personnel and
healthcare professionals to trial group allocation, thereby
minimizing the potential for bias. This is important
because knowledge of trial group allocation can lead to
potentially biased assessments of outcomes, especially
for subjective measures such as patient-reported pain
scores4,5, and may affect the co-interventions delivered
by clinicians or sought by patients. Although pharma-
ceutical studies involving placebo drugs are common,
placebo-controlled trials of invasive interventions, includ-
ing surgery, remain rare.
One of the main challenges arises from ethical concerns
about the potential risks arising from exposing patients to
placebo interventions requiring incisions (or other forms
of access to the body) and the use of anaesthesia. Closely
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linked is the issue of acceptability of such interventions to
clinicians and patients allocated to the placebo group6–8.
Invasive placebo interventions are also challenging prac-
tically to design and deliver. It can be difficult to ensure
that a placebo intervention is indistinguishable from the
treatment, owing to the invasive nature and intrinsic role
of surgeons and clinical staff in delivering the interven-
tion. Furthermore, as invasive interventions are com-
plex, comprising multiple interacting components and
co-interventions9, it can be difficult to decide which com-
ponents should and should not be included within the
placebo intervention.
A typology10 was developed with the aim of facilitat-
ing the systematic and comprehensive identification of
individual components and steps of invasive treatment
interventions. Although this is useful, the design of inva-
sive placebo interventions requires additional considera-
tions, such as identification of the treatment component(s)
believed to provide the therapeutic benefit (critical surgical
element(s)11), minimization of risks, and the selection and
monitoring of co-interventions and placebo optimization
strategies to ensure blinding.
Given the complexities inherent in the design and deliv-
ery of invasive placebo-controlled trials, including asso-
ciated ethical considerations, careful consideration of the
design of invasive placebo interventions is important. The
aim of this study was to develop a framework to inform the
optimal design and delivery of invasive placebo interven-
tions for use in RCTs.
Methods
Development of the framework was informed by the fol-
lowing steps: expanding the scope of the typology10 to facil-
itate deconstruction of invasive treatment interventions
where access to the body ismade via incision, natural orifice
and percutaneous puncture; identification of placebo opti-
mization strategies from the published literature; review of
a preliminary framework by key stakeholders attending an
international expert meeting; and refinement of the frame-
work in light of stakeholder feedback.
Identification of published placebo-controlled
trials of invasive procedures
Articles reporting a protocol or results of RCTs comparing
an invasive intervention with placebo, in living humans,
identified by a previous systematic review12 were included.
Articles published between database inception and 31
December 2017 were retrieved from OVID MEDLINE,
Embase and the Cochrane Central Register of Controlled
Trials (Central) electronic databases. Search concepts
related to RCTs, surgery and placebo were used12,13.
Additional RCTs, with no restriction on publication
date, were identified by hand searching references of
included articles and expert knowledge. Invasive interven-
tions, where access to the body was gained by incision,
percutaneous puncture or endoscopic techniques, were
included. In accordance with the review of Wartolowska
and colleagues13, placebo interventions included surgi-
cal placebo, sham surgery, or any intervention intended
to mimic the active intervention. Excluded were RCTs
evaluating medicinal products (including those delivered
before, during and after the invasive procedure) and dental
interventions, non-randomized studies, reviews, editorials,
letters or conference abstracts.
Included articles were then reviewed to revise the origi-
nal typology and identify components of treatment inter-
ventions not previously included; and to identify placebo
optimization strategies used to ensure blinding of patients
and trial personnel to trial group allocation (treatment or
placebo)14.
Revising scope of original typology
Section 1 of the original typology, relating to the identifi-
cation of components delivered within invasive treatment
interventions, was updated using methods reported
previously10. The scope of the typology was widened
to permit deconstruction of not only invasive treat-
ment interventions with incisions, but also those where
access to the body is gained via a natural orifice or
percutaneous puncture15. Additionally, the typology was
expanded to identify co-interventions delivered to patients.
Co-interventions were defined as any additional diagnos-
tic or therapeutic interventions delivered to patients as
part of the treatment protocol before, during or after the
treatment intervention.
Using a deductive approach, the typology was modi-
fied iteratively to incorporate any components reported in
descriptions of treatment interventions in the published
literature not previously included in the typology. The
process of iterative modifications consisted of assigning
descriptive labels to all reported information about invasive
interventions. These labels then informed the addition or
modification of components within the typology. Subsets
of articles were read and re-read to understand the data.
Where required, existing components of the typology were
amended and additional components added. This process
was repeated until saturation had been achieved16, that is
no additional descriptive labels emerged from the articles
that required further changes to the typology. The research
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Table 1 Revised typology with potential components of invasive treatment interventions, including co-interventions
Component Description
Anaesthesia* Details of type of anaesthesia delivered to patients, including sedation, local and general anaesthetic
Before access to body (in procedure room) Events associated with surgical intervention occurring before access to body is gained, e.g. patient
positioning, skin preparation, hair removal, dressing in surgical scrub
Access* Method used to gain access to body. Broadly this can be categorized as incision with cut, through
natural orifice or percutaneous puncture
Dissection Process of exposing an organ, tissue or structure
Irrigation* Application of any solution across or within an open wound or inside body to achieve wound hydration,
remove debris, or assist with visual examination
Resection Removal of all or part of an organ, tissue or structure
Haemostasis Stopping of bleeding or arrest of blood circulation in an organ, tissue or structure
Reconstruction Process of rebuilding, repairing or replacing an organ, tissue or structure. This may include an
anastomosis (connection between 2 structures) or insertion of a surgical adjunct such as a mesh or
prosthesis
Insertion of surgical adjunct This relates to insertion of surgical adjuncts not related directly to reconstruction, but inserted during
surgical procedure (e.g. drains or feeding tubes)
Intraoperative diagnosis Further characterization of disease process or anatomy during surgical procedure (e.g. intraoperative
cholangiography, blue dye tests or scintigraphy)
Closure/removal of equipment* Process of closing incision(s) or removing equipment from body
After skin closure Any event associated with surgical intervention but undertaken after skin closure (e.g. application of
dressings or bandages)
Co-interventions* Any co-interventions delivered to patients before, during or after invasive intervention
Other Any other component not listed above
*Revised typology components.
team met regularly to discuss all findings. The iterative
nature of this process allowed the study team to be con-
fident that no descriptions of treatment interventions were
emerging from the published studies that required further
changes to the typology.
Identification of placebo optimization strategies
Published literature was reviewed to identify reported
strategies for optimizing blinding of patients and trial per-
sonnel to trial group allocation (treatment or placebo)14.
Where placebo optimization strategies identified shared
commonalities, they were grouped. For example, strate-
gies aiming to manipulate sensory input were grouped,
whether this was through sensory deprivation (such as
visual masking) or the delivery of additional sensory cues
(for example, verbal cues to simulate treatment compo-
nents in the placebo group).
Review of preliminary framework by key
stakeholders
A preliminary framework was presented to key stakehold-
ers attending a 2-day workshop, ‘Methods for Placebo
Comparator Group Selection and Use in Surgical Trials’
in December 2018. This workshop was commissioned
and jointly funded by the UK Medical Research Council
(MRC) and the UKNational Institute for Health Research
(NIHR), with support from the Bristol Biomedical
Research Centre, in response to a commissioned call for
a state-of-the-art workshop on this topic. The workshop
covered several other aspects of placebo surgery, including
definitions, ethics and trial conduct. Attendees were invited
based on their national and international expert knowledge
in surgical trial methodology, medical ethics and consensus
methods, and included surgeons, trialists, funders, ethicists
and patient representatives. The preliminary framework
was based on: deconstruction of the treatment intervention
using the refined typology; identification and omission
of the critical surgical element; and use of placebo opti-
mization strategies identified in the literature. This was
presented formally during a dedicated session, and atten-
dees were given the opportunity to discuss and provide
feedback. Detailed notes of the discussion and comments
raised by attendees were taken by dedicated note-takers.
Refinement of framework
Detailed notes outlining feedback from key stakeholders
were used to update the preliminary framework iteratively
within the study team. The final version of the framework
was agreed by full detailed discussion within the study
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Table 2 Placebo optimization strategies reported in placebo-controlled RCTs of invasive interventions
Placebo optimization strategy
No. of RCTs
(n = 78) Example – verbatim text from trial article
Sensory manipulation 54 (69)
Visual masking 13 (17) ‘..the blinding of the patient was further ensured by shielding the patients’ view with a
vertical drape and aiming the arthroscopy monitors away from the patient’s line of vision’17
Verbal cues 12 (15) ‘During the sham procedure, physician investigators were required to talk through the
procedure steps to facilitate blinding of the patient. Spoken dialogue during the sham
procedure mimicked actual use’18
Auditory cues 11 (14) ‘Saline was splashed to simulate the sounds of lavage’19
Physical cues 9 (12) ‘..the endoscope was manipulated for 30 to 40minutes to simulate the effect of rotations
and manipulations on the esophagus’20
Visual cues 5 (6) ‘Several 1ml syringes will be filled as for the active group and injection will be simulated’21
Auditory masking 3 (4) ‘..the patient received over-the-ear headphones playing music that ensured auditory
isolation and prevented hearing of communication between staff, even before sedation’22
Olfactory cues 2 (3) ‘..the methacrylate monomer was opened to simulate the odor associated with mixing of
PMMA’23
Use of devices to optimize blinding 37 (47) ‘The palatal implant insertion tools provided by the manufacturer for the placebo control
group did not include the palatal implants, but they were in all other aspects identical to
the implant insertion tools used in the treatment group receiving the implant’24
Mimicked timings 26 (33) ‘The patient was kept in the operation theatre for the amount of time required to perform an
actual arthroscopic index shoulder surgery’25
Restricting interaction between
blinded and unblinded trial
persons
11 (14) ‘Shortly before each intervention the endoscopist was informed about the patient’s group
assignment. Subsequent contact between the patient and the endoscopist was
minimised’26
Omission of intervention details in
trial-related paperwork
11 (14)
Intervention not specified in patient
notes
9 (12) A standardized operation description was written in the patients’ charts in order to deprive
the nursing staff at the hospital of information on the character of the operation’27
Patient billing delayed or withheld 2 (3) ‘Each site will be asked to delay the billing to the subjects in an attempt to keep them
blinded as to the procedure they receive. The costs of the vertebroplasty will be billed to
the subject’s insurance after the one-month evaluation’23
Unblinded procedurist delivering
component of intervention
3 (4) ‘..the catheter was connected to a lead and passed to an independent technician. The
technician then opened a sealed envelope to ascertain the randomization schedule and
covertly either connected the catheter to the generator (active IDET group) or did not
(sham placebo group). Critically, both surgeon and subject were blinded to this step’28
Numbers in parentheses are percentages.
team when no further changes were required to address
stakeholder feedback and any outstanding methodological
requirements for placebo design.
Results
A total of 96 published placebo-controlled RCTs of inva-
sive interventions were used to develop the framework12.
Most were conducted in Europe (40, 42 per cent) and the
USA (37, 39 per cent) in gastrointestinal surgery (40, 42 per
cent). Approximately two-thirds randomized fewer than
100 patients (65, 68 per cent) and 31 (32 per cent) involved
a single centre.
Revised typology
The revised typology is shown in Table 1.
Placebo optimization strategies
Seventy-eight trials (81 per cent) reported at least one
placebo optimization strategy (Table 2).
Sensory manipulation
Sensory manipulation (54 trials, 69 per cent) included
the use of cues (auditory, visual, physical and olfactory)
to simulate treatment components, and masking (auditory
and visual) to prevent patients from receiving sensory cues
about which intervention they had received.
Use of devices to optimize blinding
Thirty-seven RCTs (47 per cent) described the use
of devices to optimize blinding, including the use of
‘deactivated’ devices in the placebo intervention that were
disconnected, turned off or incapable of delivering the
intervention. In addition, where implants were delivered,
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Fig. 1 Core stages of the DITTO framework
econstruct treatment intervention, including
co-interventions
dentify critical surgical element
ake out critical surgical element
hink risk, feasibility, and role of placebo
ptimize placebo
there were examples of implant insertion tools created by
the manufacturer that did not contain the implant under
evaluation, although it was not possible to tell this exter-
nally. For example, in an evaluation of palatal implants
for snoring and obstructive sleep apnoea, Friedman and
colleagues24 used palatal implant insertion tools provided
by the manufacturer that did not contain the implant, but
were in all other aspects identical to those used in the
treatment group.
Mimicked timings
Twenty-six trials (33 per cent) used mimicked timings,
whereby patients receiving the placebo intervention spent
the same amount of time in the procedure and/or recovery
room as those receiving the treatment.
Restricting interaction between blinded and unblinded trial
persons
In 11 trials (14 per cent), the interaction between trial per-
sons with and without knowledge of trial group allocation
was deliberately restricted.
Omission of intervention details from trial-related
paperwork
In 11 trials (14 per cent), intervention details were omitted
from trial-related paperwork, for example patient notes and
hospital bills.
Unblinded procedurist delivering component of intervention
In three trials (4 per cent), specific components of both
treatment and placebo interventions were delivered by an
unblinded procedurist, in an effort to blind trial personnel
delivering the rest of the intervention.
Feedback on the preliminary framework from key
stakeholders
Two related themes emerged from stakeholder feedback:
assessment of potential risks to patients receiving a placebo
intervention, such as the need to consider risk related to
choice of anaesthesia; and using the role of the placebo
intervention in the RCT to guide placebo intervention
design. For example, in a trial to identify the mecha-
nism of therapeutic action of the treatment intervention,
it would be advantageous to design a placebo intervention
that matches the treatment in all components, except the
critical element. Conversely, if the purpose of the placebo
intervention is primarily to blind trial persons, it may not be
necessary tomaximize the treatment components delivered
in the placebo group. Rather, the use of placebo optimiza-
tion strategies and the matching of co-interventions (such
as postoperative care) may be used primarily.
Refinement of framework
The preliminary framework was revised following consul-
tation with stakeholders. The resulting DITTO frame-
work consists of five core stages that need to be considered
iteratively when designing invasive placebo interventions
(Fig. 1).
Deconstruct treatment intervention, including
co-interventions
Here, the updated typology is used to deconstruct the
treatment intervention. This results in the production of
a comprehensive list of treatment components and steps,
including co-interventions occuring before, during and
after the treatment intervention.
Identify critical surgical element
The critical surgical element(s) is then identified from the
comprehensive list of treatment intervention components.
Take out critical surgical element(s)
The critical element(s) is then removed from the proposed
placebo intervention.
Think risk, feasibility and role of placebo in trial
Once the critical surgical element(s) has been removed,
it is important to consider the inclusion of the remaining
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Table 3 Worked example showing application of DITTO framework to development of a placebo intervention for appendicectomy
Typology components Treatment intervention (appendicectomy) Placebo intervention
Anaesthesia General anaesthetic General anaesthetic
Before access to body (in
operating theatre)
Skin preparation, positioning and draping Skin preparation, positioning and draping
Access 3 incisions (sizes flexible) 3 incisions (sizes flexible)
Create pneumoperitoneum and inspect
intra-abdominal organs
Create pneumoperitoneum and inspect intra-abdominal
organs
Dissection Identify appendix Identify appendix
Mobilize appendix and dissect mesoappendix ×
Irrigation n.a. n.a.
Resection* Ligate base of appendix (stapler or endoloop) ×
Remove appendix in bag (optional) ×
Haemostasis Ligate appendicular artery (using diathermy or
clips)
×
Check for bleeding Check for bleeding
Reconstruction n.a. n.a.
Insertion of surgical adjunct n.a. n.a.
Intraoperative diagnosis n.a. n.a.
Closure/removal of equipment Closure of fascia of port(s)>5mm Closure of fascia of port(s)>5mm
Subcuticular skin sutures Subcuticular skin sutures
Infiltration of local anaesthetic (type and amount
flexible)
Infiltration of local anaesthetic (type and amount flexible)
After skin closure Apply dressings (optional) Apply dressings (optional)
Co-interventions Urinary catheter (optional) Urinary catheter (optional)
Antibiotics at time of skin incision Antibiotics at time of skin incision
Intraoperative analgesia and fluids Intraoperative analgesia and fluids
Postoperative analgesia Postoperative analgesia
Other n.a. n.a.
Placebo optimization strategies
Visual masking Eye mask while in procedure room and postprocedure recovery room
Auditory masking Headphones while in procedure room and postprocedure recovery room
Mimicked timings All patients to spend same length of time in operating theatre, recovery rooms and in hospital after procedure
Restriction of interaction
between blinded/unblinded
trial persons
Separate healthcare team not present in theatre to look after patients after procedure
Omission of intervention
details in patient notes
Operation notes kept in sealed envelope separate to patient’s medical records, only to be accessed in an
emergency†
*Critical surgical elements. n.a., Not applicable; ×, treatment step omitted from placebo appendicectomy. †With agreed unblinding protocols in
place.
components/steps, taking account of potential risk to
patients, feasibility and the role of the placebo intervention
in the RCT (for example, as a control intervention to
elucidate the treatment mechanism).
Optimize placebo
The use of placebo optimization strategies should be
considered throughout the design process. For example, if
a component of the treatment intervention is deemed
to pose an unacceptable degree of potential risk to
patients, trialists may instead consider the use of placebo
optimization strategies to simulate the delivery of this
component.
Hypothetical application of DITTO framework
to design placebo intervention in a trial
of appendicectomy versus placebo control
Table 3 illustrates the use of the DITTO framework in a
hypothetical RCT comparing placebo with appendicec-
tomy, which has been suggested to alter the clinical course
of ulcerative colitis. The appendicectomy procedure is
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deconstructed using the updated typology, and the criti-
cal surgical element identified and removed. An indication
of the potential inclusion/omission of the remaining treat-
ment components is given, as well as placebo optimization
strategies that may be used.
Discussion
Placebo-controlled trials of invasive interventions can be
challenging to conduct, and there is a need to optimize
their design and delivery. This study has used published
literature and expert opinion to develop the DITTO
framework, a standardized methodological framework
to optimize the design and delivery of invasive placebo
interventions for use in RCTs. The DITTO framework
facilitates deconstruction of invasive treatment interven-
tions, and considers systematically which components
should, and should not, be delivered within the placebo
intervention, considering issues of risk, feasibility and
scientific validity. The DITTO framework can be used
in the design and delivery of placebo-controlled trials
of invasive interventions, including surgery, to support
the generation of the ‘gold standard’ evidence that is
needed to underpin delivery of these common healthcare
interventions29.
Previous work regarding the design of invasive placebo
interventions specifically is limited. Pilot and feasibil-
ity work conducted before placebo-controlled trials of
invasive interventions has highlighted the importance of
assessing patient and clinician acceptability during trial
design6,7. This includes assessment of the potential risk
of delivering components of the treatment intervention
in the placebo, including anaesthesia6. Assessment of risk
and careful trial design is highlighted across publications
examining the use of invasive placebo interventions in
RCTs4,30,31. Risk assessment coupled with consideration
of how to optimize scientific validity, by ensuring that
the placebo effectively mimics the treatment interven-
tion using placebo optimization strategies while minimiz-
ing risk, are key aspects of the DITTO framework. The
use of an invasive placebo intervention that fails to blind
key trial persons adequately may reflect poor trial design,
produce biased results and be difficult to justify ethically.
These considerations mirror those important in placebo
drug development; not only must the placebo tablet be
matched to treatment in terms of visual appearance, size
and weight, but assessments of the constituents of the
placebo to ensure their inert or inactive status must also
be conducted32.
A limitation of the DITTO framework in its current
form is that does not specify how assessments of risk
and feasibility of including components in the placebo
intervention may take place. For example, interviews and
focus groups with key stakeholders may be used in pilot
and feasibility work before the main trial6. The use of pilot
and feasibility work, which may also provide an opportu-
nity to test placebo optimization strategies7 and determine
the critical surgical element(s), has not been considered
explicitly in the current framework, but is important to
consider in future work. Identifying which component(s)
provides the critical therapeutic benefit may be difficult,
and the degree to which the remaining components con-
tribute to the treatment effect of the intervention requires
consideration. In this regard, stakeholder interviews and/or
consensus work before the main trial would be important
to determine which components should be omitted from
the placebo. Furthermore, although the updated typology
provides a comprehensive list of components that may be
delivered within the treatment intervention, the number
and type of steps within any component are likely to vary
widely depending on the invasive intervention. Thus, it is
not possible to include in the typology individual treat-
ment steps that would be universally applicable10. How-
ever, expansion of the typology to include a wider array
of potential treatment co-interventions may be possible.
Future work to develop the framework should incorporate
these issues. Piloting of the framework in RCTs of inva-
sive interventions will facilitate development as well as help
assess its usefulness in practice. Fostering links with pro-
fessional bodies such as the Royal College of Surgeons of
England and key stakeholders, including surgeons, funders,
journal editors and clinical trials units, will also provide
opportunities for further development and implementa-
tion of DITTO. Specifically, publication of the framework
and presentation at international trials methodology con-
ferences and national Royal College of Surgeons’ surgical
trials centre meetings will promote development and use of
the framework. Future plans to ensure uptake also include
an interactive website to facilitate use of DITTO at the
point of trial design.
Development work and dissemination may also con-
solidate the role of the DITTO framework in facilitat-
ing the transparent reporting of interventions delivered
within placebo-controlled trials of invasive procedures.
Both the TIDieR (template for intervention description
and replication)33 and SPIRIT (Standard Protocol Items:
Recommendations for Interventional Trials)34 checklists
aim to enhance the transparent reporting of interven-
tions, including surgery. TheDITTO framework can facil-
itate adherence to these guidelines by supporting the
deconstruction of the treatment intervention into its con-
stituent components. Furthermore, although the TIDieR
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and SPIRIT guidelines do not mention invasive placebo
interventions specifically, the detailed consideration given
to the content of the placebo intervention in DITTO
would also promote the transparent reporting of the com-
ponents and co-interventions delivered within the placebo.
It is expected that future work will develop reporting guide-
lines specifically for placebo-controlled trials of invasive
procedures.
The DITTO framework provides a formalized, system-
atic approach to the design and delivery of invasive placebo
interventions, which pose specific ethical and practical
challenges. Use in future trials of invasive healthcare inter-
ventions, including surgery, will support the continued
methodological advancements in this area35,36. This is key
for the generation of high-quality research data to underpin
evidence-based clinical practice.
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